Cargando…

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer

Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune checkpoint inhibitor antibody, developed by Bristol-Myers Squibb Inc., has activity across non–small cell lung cancer (NSCLC) histologies and is Food and Drug Administration approved for treatment of metastatic squamous NSCLC with progre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phillips, Therese, Simmons, Pauline, Inzunza, Hector D., Cogswell, John, Novotny, James, Taylor, Clive, Zhang, Xiaoling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561627/ https://www.ncbi.nlm.nih.gov/pubmed/26317305 http://dx.doi.org/10.1097/PAI.0000000000000256

Ejemplares similares

Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma
por: Phillips, Therese, et al.
Publicado: (2018)

Programmed death-ligand 1 (PD-L1) expression in various tumor types
por: Grosso, Joseph, et al.
Publicado: (2013)

Immunohistochemistry (IHC) staining of in-vitro cancer cell-generated tumoroids
por: Amereh, Meitham, et al.
Publicado: (2023)

IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples
por: Varghese, Frency, et al.
Publicado: (2014)

Quantitative comparison of PD-L1 IHC assays against NIST standard reference material 1934
por: Sompuram, Seshi R., et al.
Publicado: (2022)

Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx
por: Kalpakoff, Megan, et al.
Publicado: (2021)

Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
por: Novotny, J. F., et al.
Publicado: (2016)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay
por: Goud, Kalal Iravathy, et al.
Publicado: (2012)

Quantitative immunohistochemistry (IHC) analysis of biomarker combinations for human esophageal squamous cell carcinoma
por: Gao, Jiebing, et al.
Publicado: (2021)

The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
por: Taube, Janis M, et al.
Publicado: (2020)

Comparability of PD‐L1 immunohistochemistry assays for non‐small‐cell lung cancer: a systematic review
por: Koomen, Bregje M, et al.
Publicado: (2020)

Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types
por: Krigsfeld, Gabriel S, et al.
Publicado: (2020)

Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021)

An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1
por: Cogswell, John, et al.
Publicado: (2016)

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
por: Torlakovic, Emina, et al.
Publicado: (2019)

Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer
por: Sui, Weiguo, et al.
Publicado: (2009)

Correction: The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
Publicado: (2020)

On clustering for cell-phenotyping in multiplex immunohistochemistry (mIHC) and multiplexed ion beam imaging (MIBI) data
por: Seal, Souvik, et al.
Publicado: (2022)

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer
por: Roach, Charlotte, et al.
Publicado: (2016)

The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer
por: Lee, Yong Seok, et al.
Publicado: (2021)

Automated sequential chromogenic IHC double staining with two HRP substrates
por: Petersen, Kenneth Heesche, et al.
Publicado: (2018)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
por: Vennapusa, Bharathi, et al.
Publicado: (2019)

Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
por: Yeong, Joe, et al.
Publicado: (2022)

Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
por: Maule, Jake G, et al.
Publicado: (2022)

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019)

Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

Automated Protein Localization of Blood Brain Barrier Vasculature in Brightfield IHC Images
por: Soans, Rajath E., et al.
Publicado: (2016)

PD-L1 testing by immunohistochemistry in immuno-oncology
por: Vranic, Semir, et al.
Publicado: (2023)

Automated analysis of images for molecular quantification in immunohistochemistry
por: Guirado, Ramon, et al.
Publicado: (2018)

Immunohistochemistry
por: HAWES, DEBRA, et al.
Publicado: (2009)

Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
por: Velcheti, Vamsidhar, et al.
Publicado: (2018)

A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies
por: Batenchuk, Cory, et al.
Publicado: (2018)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative
por: Ma, Di, et al.
Publicado: (2016)

Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay
por: Danziger, Natalie, et al.
Publicado: (2023)

Targeted RNA‐sequencing assays: a step forward compared to FISH and IHC techniques?
por: Tachon, Gaëlle, et al.
Publicado: (2019)

Multiplex HPV RNA in situ hybridization/p16 immunohistochemistry: a novel approach to detect papillomavirus in HPV-related cancers. A novel multiplex ISH/IHC assay to detect HPV
por: Zito Marino, Federica, et al.
Publicado: (2020)

Nuclear IHC enumeration: A digital phantom to evaluate the performance of automated algorithms in digital pathology
por: Niazi, Muhammad Khalid Khan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_s1pcfjlgrdg9m189mq90hgr8sa